Viewing Study NCT00232284



Ignite Creation Date: 2024-05-05 @ 12:03 PM
Last Modification Date: 2024-10-26 @ 9:19 AM
Study NCT ID: NCT00232284
Status: COMPLETED
Last Update Posted: 2015-06-26
First Post: 2005-10-02

Brief Title: Treatment of Comorbid Depression and Substance Abuse in Young People
Sponsor: Dan Lubman
Organization: Melbourne Health

Study Overview

Official Title: An Integrated Pharmacological and Psychological Approach to Young People With Comorbid Depression and Substance Abuse
Status: COMPLETED
Status Verified Date: 2015-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study aims to treat young people with an adjunctive integrated cognitive behavioral therapy CBT intervention and to examine the acceptability of this treatment approach within this population The study will also include a pilot placebo-controlled trial of sertraline for those young people who fail to or only partially respond to the CBT intervention so as to determine whether adjunctive anti-depressant treatment improves clinical response in this population
Detailed Description: The high prevalence of co-occurring depressive and substance use disorders amongst young people is especially problematic given the significant negative impact on both symptom course and outcome reported in adult samples Whilst the clinical and functional outcomes in young people with comorbid disorders remains largely unknown of particular concern is the consistent association between depression substance misuse and suicidality in young people especially given the high rates of youth suicide in Australia As such it is both a clinical priority and an important public health goal that the clinical characteristics and outcomes of young people with comorbid depression and substance abuse are identified and that effective biopsychosocial interventions are developed that encompass predictors of treatment such that targeted integrated treatments may be offered wherever affected young people present

Whilst there is strong evidence for both selective serotonin reuptake inhibitors SSRIs and CBT in the treatment of depression and some support for their utility in alcohol dependence no studies have examined their utility in a group of young people with comorbid depression and substance abuse In fact whilst CBT is suggested to be the first-line treatment for depression in young people its role in comorbid disorders is less clear and there is little data on predictors of treatment outcome in this population Which young people best respond and which do not are important questions when designing the most appropriate interventions for real-world clinical settings In this regard the role of anti-depressants in comorbid populations also remains contentious especially amongst those that fail or only partially respond to CBT In particular it is unclear at what stage anti-depressants should be offered or even whether SSRIs are indeed effective in this population

Research Questions This project encompasses two complementary studies that aim to examine the characteristics and outcomes of young people with comorbid depression and substance abuse Stage 1 is a preliminary naturalistic investigation of the characteristics of young people with comorbid depressive and substance use disorders presenting to drug treatment and mental health services and describes their outcomes over 6 12 and 24 months This study seeks to explore what happens to these young people in the current service system in terms of engagement and treatment and related substance use and mental health outcomes Stage 2 aims to treat a sub-sample of these young people with an adjunctive integrated CBT intervention and to examine the acceptability of this treatment approach within this population In addition this study seeks to explore predictors of treatment outcome so as to inform the further development of this integrated intervention Stage 2 will also include a pilot placebo-controlled trial of sertraline for those young people who fail to or only partially respond to the CBT intervention so as to determine whether adjunctive anti-depressant treatment improves clinical response in this population

The specific aims of the study are

To describe the course of depressive disorders amongst young people with comorbid substance use disorders
To explore predictors of treatment response to an integrated CBT intervention
To explore the acceptability of the CBT intervention within a comorbid youth population
To explore the role of sertraline in the treatment of non-response to CBT in a comorbid youth population

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None